wet AMD Trials

Opthea met the primary endpoint of a superior gain in visual acuity in a 366 patient Phase 2b wet AMD study comparing OPT-302 combination therapy with standard of care treatment

DME Trials

Opthea has reported positive outcomes from a Phase 1b/2a study investigating OPT-302 administered in combination with anti-VEGF-A therapy for the treatment of persistent/refractory central-involved diabetic macular edema (DME)

Opthea’s Purpose

Opthea is developing a novel therapeutic, OPT-302, to improve vision and reduce retinal swelling in patients with eye diseases that affect the back-of-the-eye or retina.

Wet (neovascular) age-related macular degeneration (wet AMD) and diabetic macular edema (DME) are the leading causes of visual impairment in the elderly and diabetic populations respectively.  Globally, progressive vision loss associated with wet AMD and DME contributes to significant healthcare and economic costs and greatly impacts patient independence and quality of life.  Current treatment options for wet AMD and DME patients are limited and work sub-optimally in the majority of patients.

With the prevalence of both diseases on the rise given the aging population and rising incidence of diabetes worldwide, and the suboptimal responses many patients experience to standard of care therapies,  there remains a significant market opportunity for novel therapies that can improve vision in patients with these diseases.

OPT-302 is Opthea’s Phase 3-ready product candidate, designed to inhibit VEGF-C and VEGF-D and to be used in combination with standard of care VEGF-A inhibitors.  OPT-302 combination therapy achieves broader inhibition of the VEGF family, targets a mechanism of clinical resistance to existing treatments and has the potential to improve visual acuity in patients with retinal eye diseases.